Related Experiment Videos
[Carcinoma in situ in the urinary bladder].
Lijecnicki Vjesnik
|October 26, 2000
Summary
Carcinoma in situ of the urinary bladder, a rare cancer, was diagnosed in seven patients via urine sediment and biopsies. Local immunotherapy or chemotherapy achieved complete response in all patients, with a low recurrence rate.
Area of Science:
- Urology
- Oncology
- Pathology
Context:
- Carcinoma in situ (CIS) of the urinary bladder is a rare intraepithelial form of transitional cell carcinoma.
- First described in 1952, CIS presents diagnostic challenges due to potential misinterpretation of irritative urinary symptoms.
- CIS can occur independently or in association with papillary bladder tumors.
Purpose:
- To present seven cases of urinary bladder carcinoma in situ.
- To highlight diagnostic methods including urine cytology and histopathology.
- To evaluate treatment outcomes and recurrence rates following local immunotherapy or chemotherapy.
Summary:
- Seven patients with urinary bladder CIS were identified through malignant cells in urine sediment and confirmed by random bladder biopsies.
- Five cases were associated with papillary tumors, while two were primary CIS.
- All patients experienced a complete response to local immunotherapy or chemotherapy, with a low recurrence rate observed during follow-up (23-61 months).
Impact:
- Demonstrates the effectiveness of local immunotherapy and chemotherapy for treating urinary bladder CIS.
- Emphasizes the importance of considering CIS in patients with irritative urinary symptoms.
- Provides valuable long-term follow-up data on treatment outcomes and recurrence for this rare condition.